SCHEMBL5149235

SCHEMBL5149235

CC(C)n1nc(-c2nc(-c3ccsc3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.39
ADORA1 P30542 2/20 0.39
RET P07949 3/20 0.37
ATR Q13535 1/20 0.37
FGFR1 P11362 3/20 0.35
FGFR2 P21802 3/20 0.35
FGFR3 P22607 3/20 0.35
PTGER1 P34995 1/20 0.34
BMPR1B O00238 2/20 0.34
BMPR1A P36894 2/20 0.34
TGFBR1 P36897 2/20 0.34
ACVRL1 P37023 2/20 0.34
ACVR1 Q04771 2/20 0.34
TP53 P04637 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
GLO1 Q04760 1/20 0.33
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147958 0.90 ADORA2A (0.39) ADORA2AADORA1RETFGFR1FGFR2
SCHEMBL5149086 0.87 ADORA2A (0.36) ADORA2AADORA1FGFR1FGFR2FGFR3
Iodide SCHEMBL5150934 0.85 ADORA2A (0.35) ADORA2AADORA1RETFGFR1FGFR2
SCHEMBL5154867 0.83 ALDH1A1 (0.40) ADORA2AADORA1RETPTGER1TP53
SCHEMBL5149204 0.82 RAB9A (0.38) ADORA2AATRTP53KDM5BMEN1
SCHEMBL5152920 0.82 FGFR2 (0.48) FGFR1FGFR2FGFR3
SCHEMBL5152683 0.82 PIK3CD (0.45) ADORA2AADORA1RETATRFGFR1
SCHEMBL5149253 0.82 MET (0.39) ADORA2AADORA1RETFGFR1FGFR2
SCHEMBL5152533 0.81 ADORA2A (0.39) ADORA2AADORA1RETATRFGFR1
SCHEMBL5149110 0.81 PDE1A (0.41) ADORA2AADORA1RETFGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 ADORA2A 1/4885ADORA1 3/4885RET 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.